Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haleon’s separation from GSK created a consumer-health giant with dozens of power brands—and a web of disclosures that can overwhelm even seasoned analysts. Sales are broken out across oral care, pain relief, vitamins and more, while its first standalone Form 20-F runs hundreds of IFRS-heavy pages. If you have ever asked, "Where do I find Haleon insider trading Form 4 transactions" or "How do I decode Haleon’s quarterly earnings report 10-Q filing?", you know the challenge.
Stock Titan solves it. Our AI reads every new filing the moment it hits EDGAR, then delivers plain-English summaries, red-flags and searchable key terms. Whether you need Haleon Form 4 insider transactions in real-time, a side-by-side view of segment revenue from the latest 6-K, or want Haleon SEC filings explained simply, the platform highlights what matters: advertising spend trends, litigation provisions, post-spin debt covenants and more. Long-tail queries such as "Haleon executive stock transactions Form 4", "understanding Haleon SEC documents with AI", or "Haleon earnings report filing analysis" resolve to the exact section—no scrolling required.
All filing types are here, updated continuously: the Haleon annual report 10-K simplified (20-F), Haleon proxy statement executive compensation, and every Haleon 8-K material events explained. Use our tools to:
- Track insider buying and selling before marketing launches
- Compare vitamin and mineral supplement growth quarter-over-quarter
- Spot supply-chain disclosures in material event filings
Haleon plc completed a tranche of its share buyback programme, acquiring 5,214,540 ordinary shares (â£0.01 each) on 17 September 2025. The company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 14,573,545 are held in treasury, leaving 8,937,780,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company's investor website.
Haleon plc announced the purchase of 5,357,044 ordinary shares of £0.01 each under the second tranche of its buyback programme. The company will hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 9,359,005 are held in treasury, leaving 8,942,994,643 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided link and on the company's investor website. The announcement notes this does not constitute an offer for securities.
Haleon plc purchased 1,500,000 ordinary shares under the second tranche of its buyback programme announced 31 July 2025. The shares were bought on 15 September 2025 on the London Stock Exchange/CBOE (UK)/CXE and the company intends to hold the purchased shares as treasury shares.
After settlement the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 4,001,961 are held as treasury shares, leaving 8,948,351,687 ordinary shares with voting rights. The announcement points investors to a full trade breakdown at the provided link and to Haleon's investor website for details.
Haleon plc announced on 15 September 2025 that it purchased 997,991 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Of the purchased shares, 23,788 will be cancelled and 974,203 will be held as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares of each, with 2,501,961 held as treasury shares and 8,949,851,687 shares with voting rights.
The announcement notes a full trade breakdown is available via the provided RNS link and on the company's investor website.
Haleon plc reports the purchase and cancellation of 172,878 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,952,651,173 ordinary shares, of which 1,580,205 are held as treasury shares, leaving 8,951,070,968 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company website.
Haleon plc (LSE/NYSE: HLN) disclosed a notification under the UK Market Abuse Regulation for a transaction by a Person Discharging Managerial Responsibilities (PDMR). The Company received the notice on 10 September 2025 and reported an executed trade of 34 matching shares at a price of £3.6182 per share. The filing is a routine regulatory disclosure of insider dealing activity and includes the Company’s principal office address in Weybridge, Surrey.
The document also lists Haleon’s consumer brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, and directs readers to www.haleon.com for more information. The filing contains transaction detail limited to volume and price; other typical fields are present in template form but not populated with additional substantive data.
Haleon plc announced the purchase and cancellation of 1,590,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, the company's registered share capital is 8,952,824,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,951,243,846 ordinary shares with voting rights. The announcement directs readers to a full trade breakdown under the Market Abuse Regulation and notes the notice does not constitute an offer for securities. Contact and investor website information are provided.
Haleon plc reports the purchase and cancellation of 1,200,000 ordinary shares under the second tranche of its share buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,954,414,051 ordinary shares of £0.01 each, with 1,580,205 held as treasury shares, leaving 8,952,833,846 ordinary shares with voting rights. The announcement notes a full breakdown of individual trades is available via the provided link and on the company website. The notice clarifies it is not an offer for securities and provides contact/signature details for the company secretary.
Haleon plc (LSE/NYSE:HLN) announced PDMR notifications describing grants of share awards under its Share Value Plan and Performance Share Plan. The Performance Share Plan (Interim) awards vest in March 2028 subject to continued employment and performance conditions covering the period ending 31 December 2027; the relevant performance targets were disclosed in Haleon’s 2024 Annual Report and Form 20-F. The Share Value Plan (Buyout) awards are subject to continued employment. All awards were made in line with Haleon’s Directors' Remuneration Policy and are subject to malus and clawback provisions.
The filing discloses aggregate award volumes including items of 192,571 and 405,911 (shares/ADS) and notes that some volumes are Nil where applicable. No financial amounts, prices, or additional compensation details are provided in this report.
Haleon plc announced on 05 September 2025 that it purchased and cancelled 353,360 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,955,614,051 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,951,733,846 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company website. The announcement states it does not constitute an offer or solicitation in any jurisdiction.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
